ストックスクリーナーアプリを入手
13.55
0.44%
-0.06
プレマーケット:
13.20
-0.35
-2.58%
Cullinan Therapeutics Inc (CGEM) 最新ニュース
CGEM Stock Price, Quote & Chart - ChartMill
CGEM Reiterated by Wedbush -- Price Target Maintained at $37 - GuruFocus
Cullinan Therapeutics: Heading Toward Paydirt (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics reports remissions in SLE, RA with CLN-978 - scanx.trade
William Blair reiterates Cullinan Oncology stock rating on trial data By Investing.com - Investing.com South Africa
William Blair reiterates Cullinan Oncology stock rating on trial data - Investing.com
CGEM: CLN-978 and velinotamig show breakthrough efficacy and safety in refractory autoimmune diseases - TradingView
Cullinan Therapeutics, Inc. (CGEM) Discusses Promising Clinical Data for CLN-978 and Velinotamig in Autoimmune DiseasesSlideshow (NASDAQ:CGEM) 2026-06-10 - Seeking Alpha
Cullinan Therapeutics (CGEM) Reports Positive Clinical Developme - GuruFocus
CGEM: T cell engagers show robust efficacy in RA and SLE, with expanded trials planned for 2027 - TradingView
Cullinan reports clinical data for autoimmune drug candidates - Investing.com UK
CGEM: CLN-978 and velinotamig advance toward Phase 2 after strong efficacy and safety in SLE and RA - TradingView
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data - TipRanks
Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps - Moomoo
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases - The Manila Times
Cullinan Therapeutics Shares New Clinical Data Across Its - GlobeNewswire
Cullinan Therapeutics shares positive Phase 1 data for CLN-978 and velinotamig, outlines next‑stage plans - TradingView
Cullinan Therapeutics (NASDAQ: CGEM) shares new autoimmune trial results - Stock Titan
Cullinan Aims for Autoimmune 'Reset' with T Cell Engager Data - BriefGlance
Cullinan Therapeutics details new biomarker approach for immune reset in autoimmune disease research - Traders Union
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Pfizer (PFE) and Novo Nordisk (NVO) - The Globe and Mail
Cullinan TherapeuticsExpanding The Reach Of T Cell Engagers Beyond Cancer - RTTNews
Cullinan Therapeutics, Inc.Common Stock (CGEM) Stock Price, News, Quote & History - FinancialContent
A Quick Look at Today's Ratings for Cullinan Therapeutics(CGEM.US), With a Forecast Between $30 to $38 - Moomoo
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $30 - GuruFocus
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-978 CD19xCD3 T Cell Engager in SLE and RA at EULAR 2026 Congress - Minichart
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data - TipRanks
Cullinan Therapeutics shares Phase 1 CLN-978 data showing deep B-cell depletion and clinical responses - TradingView
Cullinan Therapeutics (CGEM) posts early CLN-978 SLE and RA remission data - Stock Titan
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at E - GuruFocus
Cullinan Therapeutics (CGEM) Unveils Promising Phase 1 Data at EULAR Congress - GuruFocus
Cullinan Therapeutics Inc Cln-978 Shows Favorable Safety Profile With Single Target Doses Up To 30 Μg As Well As Initial Multi-Dose Regimen - TradingView
Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA - Traders Union
Cullinan Therapeutics Reports Positive Clinical Data for CLN-978 in Treating Systemic Lupus Erythematosus and Rheumatoid Arthritis - Quiver Quantitative
Cullinan Therapeutics Presents Initial Clinical Data for - GlobeNewswire
Cullinan Therapeutics Presents Initial Clinical Data for Cln-978, A Cd19xcd3 T Cell Engager, At the Eular 2026 Congress - marketscreener.com
Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors - TipRanks
Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments - Traders Union
Number of shareholders of Cullinan Therapeutics, Inc. – NASDAQ:CGEM - TradingView
BTIG Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $38 - Moomoo
CGEM Technical Analysis | Trend, Signals & Chart Patterns | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Cullinan Therapeutics (CGEM) Stock Analysis Report | Financials & Insights - Benzinga España
Cullinan Therapeutics (CGEM) Retreats 1% as Stock Approaches Support ZoneIV Percentile - The Legal Advocate
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), Cullinan Management (CGEM) - The Globe and Mail
Cullinan Therapeutics (CGEM) Plans Immunology Day Event in NYC - GuruFocus
CGEM - Finviz
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager - The Manila Times
Cullinan Therapeutics to Host Immunology Day to Showcase - GlobeNewswire
Wedbush maintains Cullinan Therapeutics (CGEM) outperform recommendation - MSN
Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Cullinan Therapeutics, Inc. $CGEM Shares Sold by Blue Owl Capital Holdings LP - MarketBeat
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Climb Bio (CLYM) and Boston Scientific (BSX) - The Globe and Mail
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):